Constitutive cyclo-oxygenase-2 does not contribute to the development of human visceral pain hypersensitivity

European Journal of Pain

Volumn 10, Issue 6, 2006, Pages 487-

  Willert, Robert P ^a   Delaney, Claire ^a   Hobson, Anthony R ^a   Thompson, David G ^a   Woolf, Clifford J ^b   Aziz, Qasim ^a  

^a HOPE HOSPITAL   (United Kingdom)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

COX 2; Oesophagus; Valdecoxib and central sensitisation; Visceral hypersensitivity

Indexed keywords

CYCLOOXYGENASE 2; HYDROCHLORIC ACID; PARECOXIB; PLACEBO; SODIUM CHLORIDE; VALDECOXIB;

ABSENCE OF SIDE EFFECTS; ADULT; ALLODYNIA; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ATTENUATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TRANSFORMATION; ELECTROSTIMULATION; ENZYME INHIBITION; ESOPHAGUS PAIN; FOOT; HUMAN; HYPERALGESIA; PAIN THRESHOLD; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIZATION; THORAX WALL; VALIDATION PROCESS; VISCERAL PAIN;

EID: 33745379452     PISSN: 10903801     EISSN: 15322149     Source Type: Journal    
DOI: 10.1016/j.ejpain.2005.07.003     Document Type: Article

References (51)

1. Alsalameh S., Burian M., Mahr G., Woodcock B.G., and Geisslinger G. Review article: the pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor. Aliment Pharmacol Ther 17 (2003) 489-501
2. Barden J., Edwards J.E., McQuay H.J., and Moore R.A. Oral valdecoxib and injected parecoxib for acute postoperative pain: a quantitative systematic review. BMC Anesthesiol 3 (2003) 1
3. Barton S.F., Langeland F.F., Snabes M.C., LeComte D., Kuss M.E., Dhadda S.S., et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology 97 (2002) 306-314
4. Beiche F., Klein T., Nusing R., Neuhuber W., Goppelt-Struebe M., Scheuerer S., et al. Localization of cyclooxygenase-2 and prostaglandin E2 receptor EP3 in the rat lumbar spinal cord. J Neuroimmunol 89 1-2 (1998) 26-34
5. Bradete M., Pare P., Douville P., and Morin A. Visceral perception in health and functional dyspepsia. Crossover study of gastric distension with placebo and domperidone. Dig Dis Sci 36 (1991) 52-58
6. Broom D.C., Samad T.A., Kohno T., Tegeder I., Geisslinger G., and Woolf C.J. Cyclooxygenase 2 expression in the spared nerve injury model of neuropathic pain. Neuroscience 124 (2004) 891-900
7. Bueno L., Fioramonti J., Delvaux M., and Frexinos J. Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroenterology 112 (1997) 1714-1743
8. Cervero F. Sensory innervation of the viscera: peripheral basis of visceral pain. Physiol Rev 74 (1994) 95-138
9. Chavez M.L., and DeKorte C.J. Valdecoxib: a review. Clin Ther 25 (2003) 817-851
10. Cheer S.M., and Goa K.L. Parecoxib (parecoxib sodium). Drugs 61 (2001) 1133-1141 discussion 1142-3
11. Dirig D.M., Isakson P.C., and Yaksh T.L. Effect of COX-1 and COX-2 inhibition on induction and maintenance of carrageenan-evoked thermal hyperalgesia in rats. J Pharmacol Exp Ther 285 (1998) 1031-1038
12. Drosssman DA, Corazziari R, Talley NJ, Thompson WG, Whitehead WE. ROME II. The functional gastrointestinal disorders. Diagnosis, Pathophysiology and treatment: a multinational consensus, Degnon Associates, 2000.
13. Emery P., Zeidler H., Kvein T., Guslandi M., Naudin R., Stead H., et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double blind comparison. Lancet 354 (1999) 2106-2111
14. Erbersberger A., Grubb B.D., Willingale H.L., Gardiner N.J., Nebe J., and Schaible H.G. The intraspinal release of prostaglandin E2 in a model of acute arthritis is accompanied by an up-regulation of cyclo-oxygenase-2 in the spinal cord. Neuroscience 93 (1999) 775-781
15. Gebhart G.F., and Ness T.J. Visceral pain: a review of experimental studies. Pain 41 (1990) 167-234
16. Ghilardi J.R., Svensson C.I., Rogers S.D., Yaksh T.L., and Manyth P.W. Constitutive spinal cyclooxygenase-2 participates in the initiation of tissue injury-induced hyperalgesia. J Neurosci 11 (2004)
17. Haupt W., Jiang W., Kreis M., and Grundy D. Prostaglandin EP receptor subtypes have distinctive effects on jejunal afferent sensitivity in the rat. Gastroenterology 119 (2000) 1580-1589
18. Makarowski W., Zhao W.W., Bevirt T., and Recker D.P. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthr Cartilage 10 (2002) 290-296
19. Malmberg A.B., and Yaksh T.L. Antinociceptive actions of spinal nonsteroidal anti-inflammatory agents on the formalin test in the rat. J Pharmacol Exp Ther 263 (1992) 136-146
20. Malmberg A.B., and Yaksh T.L. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 257 (1992) 1276-1279
21. Malmberg A.B., and Yaksh T.L. Antinociception produced by spinal delivery of the S and R enantiomers of flurbiprofen in the formalin test. Eur J Pharmacol 256 (1994) 205-209
22. Matsumoto A.K., Melian A., Mandel D.R., McIlwain H.H., Borenstein D., Zhao P.L., et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 29 (2002) 1623-1630
23. Matthews J.N.S., Altman D.G., Campbell M.J., and Royston P. Analysis of serial measurements in clinical research. Br Med J 300 (1990) 230-235
24. Mayer E.A., and Collins S.M. Evolving pathophysiologic models of functional gastrointestinal disorders. Gastroenterology 122 (2002) 2032-2048
25. Mayer E.A., and Gebhart G.F. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 107 (1994) 271-293
26. Mayer E.A., and Raybould H.E. Role of visceral afferent mechanisms in functional bowel disorders. Gastroenterology 99 (1990) 1688-1704
27. Melzack R. The short-form McGill pain questionnaire. Pain 30 (1987) 191-197
28. Minami T., Sugatani J., Sakimura K., Abe M., Mishina M., and Ito S. Absence of prostaglandin E2-induced hyperalgesia in NMDA receptor epsilon subunit knockout mice. Br J Pharmacol 120 (1997) 1522-1526
29. Minami T., Uda R., Horiguchi S., Ito S., Hyodo M., and Hayaishi O. Allodynia evoked by intrathecal administration of prostaglandin E2 to conscious mice. Pain 57 (1994) 217-223
30. Rasmussen G.L., Steckner K., Hogue C., Torri S., and Hubbard R.C. Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. Am J Orthop 31 (2002) 336-343
31. Richter J.E., Barish C.F., and Castell D.O. Abnormal sensory perception in patients with esophageal chest pain. Gastroenterology 91 (1986) 938-943
32. Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 14 (1973) 125-132
33. Saito Y., Kaneko M., Kirihara Y., Kosaka Y., and Collins J.G. Intrathecal prostaglandin E1 produces a long-lasting allodynic state. Pain 63 (1995) 303-311
34. Samad T.A., Moore K.A., Sapirstein A., Billet S., Allchorne A., Poole S., et al. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 410 (2001) 471-475
35. Sarkar S., Aziz Q., Woolf C.J., Hobson A.R., and Thompson D.G. Contribution of central sensitisation to the development of non-cardiac chest pain. Lancet 356 (2000) 1154-1159
36. Sarkar S., Hobson A.R., Hughes A., Growcott J., Woolf C.J., Thompson D.G., et al. The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans. Gastroenterology 124 (2003) 18-25
37. Sciberras D.G., Goldenberg M.M., Bolognese J.A., James I., and Baber N.S. Inflammatory responses to intradermal injection of platelet activating factor, histamine and prostaglandin E2 in healthy volunteers: a double blind investigation. Br J Clin Pharmacol 24 (1987) 753-761
38. Seibert K., Zhang Y., Leahy K., Hauser S., Masferrer J., Perkins W., et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 91 (1994) 12013-12017
39. Seybold V.S., Jia Y.P., and Abrahams L.G. Cyclo-oxygenase-2 contributes to central sensitization in rats with peripheral inflammation. Pain 105 (2003) 47-55
40. Sorkin L. IT ketorolac blocks NMDA-evoked spinal release of prostaglandin-E2 (PGE2) and thromboxane-B2 (TXB2). Anesthesiology 79 3A (1993) A908
41. South S.M., Kohno T., Kaspar B.K., Hegarty D., Vissel B., Drake C.T., et al. A conditional deletion of the NR1 subunit of the NMDA receptor in adult spinal cord dorsal horn reduces NMDA currents and injury-induced pain. J Neurosci 23 (2003) 5031-5040
42. Svensson C.I., and Yaksh T.L. The spinal phospholipase-cyclooxygenase-prostanoid cascade in nociceptive processing. Annu Rev Pharmacol Toxicol 42 (2002) 553-583
43. Talley N.J., Phillips S.F., Melton L.J., Wiltgen C., and Zinsmeister A.R. A patient questionnaire to identify bowel disease. Ann Int Med 111 (1989) 671-674
44. Tegeder I., Niederberger E., Vetter G., Brautigam L., and Geisslinger G. Effects of selective COX-1 and -2 inhibition on formalin-evoked nociceptive behaviour and prostaglandin E(2) release in the spinal cord. J Neurochem 79 4 (2001) 777-786
45. Vanegas H., and Schaible H.G. Prostaglandins and cycloxygenases in the spinal cord. Prog Neurobiol 64 (2001) 327-363
46. Willert R.P., Woolf C.J., Hobson A.R., Delaney C., Thompson D.G., and Aziz Q. The development and maintenance of human visceral pain hypersensitivity is dependent on the N-methyl-d-aspartate receptor. Gastroenterology 126 (2004) 683-692
47. Willingale H.L., Gardiner N.J., McLymont N., Giblett S., and Grubb B.D. Prostanoids synthesized by cyclo-oxygenase isoforms in rat spinal cord and their contribution to the development of neuronal hyperexcitability. Br J Pharmacol 122 (1997) 1593-1604
48. Woolf C.J., and Thompson S.W. The induction and maintenance of central sensitization is dependent on N-methyl-d-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain 44 (1991) 293-299
49. Yaksh T.L., Dirig D.M., Conway C.M., Svensson C., Luo Z.D., and Isakson P.C. The acute antihyperalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. J Neurosci 21 (2001) 5847-5853
50. Yamamoto T., and Nozaki-Taguchi N. The role of cyclooxygenase-1 and -2 in the rat formalin test. Anesth Analg 94 (2002) 962-967
51. Yamamoto T., and Sakashita Y. COX-2 inhibitor prevents the development of hyperalgesia induced by intrathecal NMDA or AMPA. Neuroreport 9 (1998) 3869-3873